Newron Pharmaceuticals
As of the edition of 20 October 2026, Newron Pharmaceuticals runs 4 drugs, 1 of them marketed; it is on route A at 10 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Safinamide | Ends 2028 (patent) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 10 targets, route B at 0 targets.
All 10 rows on route A or B
In the product10 company-target rows on route A or B; 7 are not shown here, and no score is.
See all 10 targets where Newron Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 11 trials led
- Mental health: 3 trials led
- Cancer: 2 trials led